Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the case for establishing a reimbursement pathway for renal denervation as a treatment for resistant hypertension, given that it is approved and commercially available in a number of comparable healthcare systems internationally but is not routinely commissioned by the NHS.

NHS England is reviewing the clinical evidence for the commissioning of renal denervation treatment. The National Institute for Health and Care Excellence is an independent body with its own processes for reviewing and updating its guidance, taking account of the best available evidence of both clinical and cost effectiveness.